The Biosimilars Council Congressional Briefing: Five Takeaways

Friday May 4, 2018

Last Friday, The Biosimilars Council hosted a congressional briefing titled “Biosimilars: The Challenges and Promise of Patient Access.” AAM’s Craig Burton moderated a discussion with Molly Burich (Boehringer Ingelheim), Mark Fleury (American Cancer Society’s Cancer Action Network), Greg Gierer (America’s Health Insurance Plans) and Patrick Vallano (Mylan).

Although the speakers represented a variety of backgrounds and interests, they identified a few key principles as the U.S. biosimilars industry continues to mature:

  1. Biosimilars are safe and effective. Biosimilar medicines offer comparable safety and efficacy as their reference biologic counterparts. They do not have any clinically meaningful differences from their biologic counterparts and use the same mechanism of action. They go through the same rigorous FDA testing and review. (See “90 Studies Prove Biosimilars’ Safety And Efficacy: What Now?”)
  2. A truly competitive biosimilars market will drive down drug prices and increase patient access to lifesaving medications. Just as generic pharmaceuticals make health care more accessible for patients, biosimilars promise substantial savings—over $54 billion over the next ten years – if the right policies are put in place to ensure a robust market, according to RAND Corporation.The policy and legal pathways for creating a robust market are realistic and achievable.
  3. Europe is far ahead of the U.S. In Europe, approximately 45 biosimilars have been approved across at least eight therapeutic classes. Although there are more than 60 biosimilar medicines in development in the U.S., only 9 have been approved to date, and only three are commercially available). According to IQVIA, patient access to both biosimilars and biologics has increased by as much as 100 percent in Europe as the result of biosimilar availability.
  4. Recent updates to biosimilars reimbursement in the Medicare Program are a step in the right direction, but threats remain. In recent months, the Centers for Medicare & Medicaid Services (CMS) and Congress have taken steps to place biosimilars on a level competitive playing field with their brand biologic counterparts in the Medicare program. These updates provide consistent and competitive reimbursement for biosimilars and are crucial in ensuring the creation of a strong market for these products. However, recent attempts to strip biosimilars of their “pass-through” status threaten this emerging market.
  5. Better education of patients and providers is needed. The promise of biosimilars will increasingly be realized as doctors, pharmacists and patients gain confidence in this relatively new concept. Insurance companies and patient advocate groups can also play a part in spreading information—and debunking misinformation. When generic medications entered the market in the 1980s, similar education was needed, and patients have saved nearly $1.7 trillion over the last ten years as a result of a safe, affordable generic alternative.

Events like the “Biosimilars: The Challenges and Promise of Patient Access” briefing will continue to shape perceptions about this exciting new pharmaceutical prospect. Please stay tuned for additional materials and briefings on this topic.

View more photos from the briefing

Learn more:

About the Biosimilars Council

The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available on our about page.

About AAM

AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 23 percent of total drug spending. Additional information is available at

Stay Informed

Subscribe for Updates

Receive our monthly Biosimilars Bulletin and other important updates on biosimilars in the U.S.


Get Involved

The Council is involved in a number of events that focus on advancing biosimilars in the United States. Click on one below to learn more:



October 21–23, 2024 | Rockville, MD

GRx+Biosims™ 2024 is the leading regulatory science and policy event for the U.S. generics and biosimilars industry. Access the most recent information straight from experts at the Food and Drug Administration, grasp the latest policies shaping the industry, and acquire valuable insights to propel your professional development.